We are very pleased to share one exciting news! From November 22, 2021, Open Exploration Publishing Inc. is now official members of OASPA – the Open Access Scholarly Publishing Association. It represents the very best in open access publishing and enjoys a high reputation in the publishing industry. View Open Exploration's membership profile page, here: https://oaspa.org/member/open-exploration-publishing-inc/

As a journal of Open Exploration, Exploration of Targeted Anti-tumor Therapy provides immediate open access to all published content; all content is freely available without charge to users or their Institutes. Launched in 2020, this peer-reviewed online journal, now is indexed by CAS, DOAJ, WorldCat, CNKI Scholar, Portico, ResearchGate, etc. A total of 60 quality articles have been published online and these articles have received extensive attention, based on views/downloads/citations. We are very delighted to be joining this community of open access. With this high recognition, we are confident to make great progress in the next stage of journal development. Welcome your attention: https://www.explorationpub.com/Journals/etat

We are pleased to announce that Exploration of Targeted Anti-tumor Therapy has been accepted for indexing in Chemical Abstract Services (CAS). 

CAS is a division of the American Chemical Society. It is the most authoritative and comprehensive source for chemical information. CAS intends to help scientists benefit from the published work of their colleagues around the world by monitoring, abstracting and indexing the world's chemistry-related literature.

We are pleased to announce that Exploration of Targeted Anti-tumor Therapy is now indexed in the Directory of Open Access Journals (DOAJ), an online directory that indexes and provides access to quality open access, peer-reviewed journals. The official website of ETAT on DOAJ is https://doaj.org/toc/2692-3114

Launched in 2020, this fully Open Access cancer research journal continues to grow in scope and influence. Find out more about the journal: https://www.explorationpub.com/Journals/etat

Lately, Open Exploration joined the Initiative for Open Abstracts (I4OA) and fully support "the unrestricted availability of the abstracts of the world's scholarly publications in trusted repositories where they are open and machine-accessible". Read more about it, https://www.explorationpub.com/oep/index/17.

In October and November 2020, three well-known researchers have officially joined the Editorial Board of ETAT. They are Prof. Gareth J. Thomas, Dr. A. Emre Sayan from University of Southampton, UK, and Prof. Miguel Vicente-Manzanares from Instituto de Biologia Molecular y Celular del Cancer (CSIC), Spain. We greatly welcome their participation, and hope they will find the meaning and reward of the Editorial roles in this growing journal. Learn more about ETAT editorial board, https://www.explorationpub.com/Journals/etat/Editorial_Board.

We are very pleased to release the news that six outstanding experts in the field (mainly from genetics, lymphoma, neuro oncology, gynecological oncology, liver cancer, etc.) have joined the Editorial Board of ETAT journal since August 2020. Their recognition and support will be always remembered and appreciated greatly. We warmly welcome their participation and look forward to developing the journal to the next level together.

Associate Editors:

Prof. Francesco Bertoni, MD

Head of Lymphoma Genomics, deputy director of Institute of Oncology Research, Faculty of Biomedical Sciences, USI, Bellinzona, Switzerland. Vice-president of SAKK Project Group Lymphoma.

Prof. Antonio Giordano, MD, PhD

Present Professor, Department of Biology and Medicine; Present Director, Sbarro Health Research Organization; Present Director, Center of Biotechnology; Present Director, Professional Master Program (PSM) in Bioinnovation; Temple University, Philadelphia, PA, USA. Present “Chiara Fama” Professor, Department of Medical Biotechnology, University of Siena, Italy.

Prof. Chunsheng Kang, MD, PhD

Deputy Director of Tianjin Neurology Institute, Director of neuro-tumor laboratory of Tianjin Medical University General Hospital, Tianjin, China. Vice Chairman of Glioma Committee of the Chinese Medical Doctor Association, Chairman of the 2nd Basic and Transfer Chemistry Group, and Permanent Member of Glioma Committee of the Chinese Anti-Cancer Association.

Prof. Maurie Markman, MD

President, Cancer Treatment Centers of America Medicine & Science; Chief Clinical Officer, CTCA Health, Philadelphia, PA, USA.

Prof. Massimo Di Maio, MD

Director, Division of Medical Oncology, A.O. Ordine Mauriziano; Associate Professor of Medical Oncology, Department of Oncology, University of Turin, Torino, Italy.

Editorial Board Member:

Prof. Lorenza Rimassa, MD

Associate Professor of Medical Oncology, Department of Biomedical Sciences, Humanitas University; Deputy Director, Medical Oncology Unit, Humanitas Cancer Center, Humanitas Research Hospital, IRCCS, Milano, Italy. Member of the Italian Association of Medical Oncology (AIOM), the European Society for Medical Oncology (ESMO), the American Society of Clinical Oncology (ASCO), the European Association for the Study of the Liver (EASL), and the International Liver Cancer Association (ILCA).

Exploration of Targeted Anti-tumor Therapy always endorses and applies the standards and recommendations of the ICMJE, to ensure the rigorousness of review and publication process. Now, the journal has been recognized in the list of "Journals stating that they follow the ICMJE Recommendations". Learn more about the information via http://www.icmje.org/journals-following-the-icmje-recommendations/.